Search

Your search keyword '"Stary, J."' showing total 12 results
Start Over Author "Stary, J." Journal hemasphere
12 results on '"Stary, J."'

2. P816: TRANSIENT MONOSOMY 7 IN SAMD9/9L SYNDROMES: IS IT SAFE TO WATCH AND WAIT?

Author

Erlacher, M., primary, Andresen, F., additional, Yoshimi, A., additional, Sukova, M., additional, Stary, J., additional, de Moerloose, B., additional, Dworzak, M., additional, Polychronopoulou, S., additional, Göhring, G., additional, Kratz, C., additional, van der Werff ten Bosch, J., additional, Seidel, M., additional, Strahm, B., additional, Wlodarski, M., additional, and Niemeyer, C., additional

Published
2022
Full Text
View/download PDF

4. PF162 FREQUENCY AND PROGNOSTIC IMPACT OF ZEB2 H1038/Q1072 MUTATIONS IN CHILDHOOD B-OTHER ACUTE LYMPHOBLASTIC LEUKEMIA

Author

Zaliova, M., primary, Potuckova, E., additional, Lukes, J., additional, Winkowska, L., additional, Starkova, J., additional, Janotova, I., additional, Sramkova, L., additional, Stary, J., additional, Zuna, J., additional, Stanulla, M., additional, Zimmermann, M., additional, Bourquin, J.-P., additional, Eckert, C., additional, Cario, G., additional, and Trka, J., additional

Published
2019
Full Text
View/download PDF

6. PB1651 INFERIOR PROGNOSIS OF TLX3 GENE REARRANGEMENTS IN PEDIATRIC T-ALL

Author

Lizcova, L., primary, Prihodova, E., additional, Pavlistova, L., additional, Sladkova, L., additional, Svobodova, K., additional, Mejstrikova, E., additional, Hrusak, O., additional, Luknarova, P., additional, Janotova, I., additional, Sramkova, L., additional, Stary, J., additional, Michalova, K., additional, and Zemanova, Z., additional

Published
2019
Full Text
View/download PDF

7. PF237 THE PROGNOSTIC IMPACT OF LYMPHOCYTE REPERTOIRE RECOVERY AFTER INDUCTION TREATMENT OF CHILDHOOD AML

Author

Svaton, M., primary, Novakova, M., additional, Reznickova, L., additional, Darzentas, N., additional, Stuchly, J., additional, Svenkrtova, A., additional, Zaliova, M., additional, Zuna, J., additional, Mejstrikova, E., additional, Kotrova, M., additional, Reigl, T., additional, Hrusak, O., additional, Stary, J., additional, Trka, J., additional, and Fronkova, E., additional

Published
2019
Full Text
View/download PDF

8. PF677 DNA HYPERMETHYLATION EMERGES AS THE STRONGEST PREDICTOR FOR POOR OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML)

Author

Niemeyer, C.M., primary, Flotho, C., additional, Lipka, D.B., additional, Buechner, J., additional, Catala, A., additional, De Haas, V., additional, De Moerloose, B., additional, Dworzak, M., additional, Fabri, O., additional, Hasle, H., additional, Jahnukainen, K., additional, Kállay, K., additional, Masetti, R., additional, Schmugge, M., additional, Smith, O.P., additional, Stary, J., additional, Turkiewicz, D., additional, Ussowicz, M., additional, Schoenung, M., additional, Erlacher, M., additional, Yoshimi, A., additional, Bierings, M., additional, Bordon, V., additional, Diaz-de-Heredia, C., additional, Horakova, J., additional, Lankaster, A.C., additional, Masmas, T., additional, Meisel, R., additional, O’Marcaigh, A., additional, Roessig, C., additional, Peters, A., additional, Pichler, H., additional, Sauer, M., additional, Sedlacek, P., additional, Zecca, M., additional, Noellke, P., additional, Strahm, B., additional, and Locatelli, F., additional

Published
2019
Full Text
View/download PDF

9. PF176 MONOCYTIC SWITCH AND DISCREPANCY BETWEEN FLOW CYTOMETRIC AND MOLECULAR MINIMAL RESIDUAL DISEASE ARE FREQUENT IN DUX4 REARRANGED AND PAX5-P80R MUTATED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

Author

Novakova, M., primary, Vakrmanova, B., additional, Slamova, L., additional, Musilova, A., additional, Bruggemann, M., additional, Ritgen, M., additional, Kolenovska, A., additional, Svec, P., additional, Fronkova, E., additional, Kalina, T., additional, Trka, J., additional, Stary, J., additional, Vaskova, M., additional, Winkowska, L., additional, Zaliova, M., additional, Fiser, K., additional, Hrusak, O., additional, and Mejstrikova, E., additional

Published
2019
Full Text
View/download PDF

10. Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol.

Author

Rizzari C, Möricke A, Valsecchi MG, Conter V, Zimmermann M, Silvestri D, Attarbaschi A, Niggli F, Barbaric D, Stary J, Elitzur S, Cario G, Vinti L, Boos J, Zucchetti M, Lanvers-Kaminsky C, von Stackelberg A, Biondi A, and Schrappe M

Abstract

The incidence of hypersensitivity reactions (HSRs) to PEG-asparaginase (PEG-ASNase) was evaluated in 6136 children with ALL enrolled in the AIEOP-BFM ALL 2009 study. Patients with B-cell precursor-acute lymphoblastic leukemia (BCP-ALL) were stratified as standard-risk/medium-risk (MR)/high-risk (HR) and those with T-ALL as non-High/HR. PEG-ASNase was administered intravenously at 2500 IU/sqm/dose. All patients received 2 PEG-ASNase doses in induction; thereafter non-HR versus HR patients received 1 versus 6 PEG-ASNase doses, respectively. After the single regular dose of PEG-ASNase at the beginning of delayed intensification, BCP-ALL-MR patients were randomized to receive 9 additional PEG-ASNase doses every 2 weeks (experimental arm [EA]) versus none (standard arm [SA]); HR patients were randomized to receive, in consolidation, 4 weekly PEG-ASNase doses (EA) versus none (SA). The HSR cumulative incidence (CI) was estimated adjusting for competing risks. An HSR occurred in 472 of 6136 (7.7%) patients. T-non- HR/BCP-Standard-Risk, BCP-MR-SA, BCP-MR-EA, HR-SA and HR-EA patients had 1-year-CI-HSR (±SE) rates of 5.2% (0.5), 5.2% (0.5), 4.0% (0.8), 20.2% (1.2), and 6.4% (1.3), respectively. The randomized intensification of PEG-ASNase did not significantly impact on HSR incidence in BCP-MR patients (1-y-CI-HSR 3.8% [0.8] versus 3.2% [0.6] in MR-EA versus MR-SA; P = 0.55), while impacted significantly in HR patients (1-y-CI-HSR 6.4% [1.3] versus 17.9% [1.8] in HR-EA and HR-SA, respectively; P < 0.001). The CI-HSR was comparable among non-HR groups and was not increased by a substantial intensification of PEG-ASNase in the BCP-MR-EA group whilst it was markedly higher in HR-SA than in HR-EA patients, suggesting that, in such a chemotherapy context, a continuous exposure to PEG-ASNase reduces the risk of developing an HSR., Competing Interests: CR: Jazz Pharmaceuticals, Servier, Clinigen, Amgen: honoraria. AM: Clinigen and BTG: consultancy honoraria. JB: institutional and personal consultation fees, advisory board memberships, invited lectures and travel and research grants from asparaginase suppliers Medac, Shire, Sigma-Tau, Baxalta, Servier, Opi, Eusapharma, Jazz in the last decade(s). Focusing on the last years restricted to institutional grants from JAZZ (research) and Servier (Consulting, research, invited lecture). MS and/or study group have received research support from SHIRE, Jazz Pharma, Servier, SigmaTau, and Novartis. Honoraria from Servier, Novartis, and Jazz Pharma. VC: Medac, Sigma-Tau and Shire: research funds; Sigma-Tau and Shire: consultancy honoraria. AA: honoraria for lectures, consultancy or advisory board participation from Jazz Pharmaceuticals, Amgen, Novartis, MSD, Amgen, Novartis, MSD, and Gilead. He has received compensation for travel expenses from Jazz Pharmaceuticals. CL-K: Clinigen: Honoraria; Servier: Travel Grants. All the other authors have no conflicts of interest to disclose., (Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.)

Published
2023
Full Text
View/download PDF

11. The EHA Research Roadmap: Malignant Lymphoid Diseases.

Author

Dreyling M, André M, Gökbuget N, Tilly H, Jerkeman M, Gribben J, Ferreri A, Morel P, Stilgenbauer S, Fox C, Maria Ribera J, Zweegman S, Aurer I, Bödör C, Burkhardt B, Buske C, Dollores Caballero M, Campo E, Chapuy B, Davies A, de Leval L, Doorduijn J, Federico M, Gaulard P, Gay F, Ghia P, Grønbæk K, Goldschmidt H, Kersten MJ, Kiesewetter B, Landman-Parker J, Le Gouill S, Lenz G, Leppä S, Lopez-Guillermo A, Macintyre E, Mantega MVM, Moreau P, Moreno C, Nadel B, Okosun J, Owen R, Pospisilova S, Pott C, Robak T, Spina M, Stamatopoulos K, Stary J, Tarte K, Tedeschi A, Thieblemont C, Trappe RU, Trümper LH, and Salles G

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results